Body mass index and survival after breast cancer diagnosis in Japanese women

被引:35
|
作者
Kawai, Masaaki [1 ,4 ]
Minami, Yuko [1 ]
Nishino, Yoshikazu [2 ]
Fukamachi, Kayoko [3 ]
Ohuchi, Noriaki [4 ]
Kakugawa, Yoichiro [3 ]
机构
[1] Tohoku Univ, Div Community Hlth, Grad Sch Med, Aoba Ku, Sendai, Miyagi 9808575, Japan
[2] Miyagi Canc Ctr Res Inst, Div Canc Epidemiol & Prevent, Natori, Miyagi 9811293, Japan
[3] Miyagi Canc Ctr Hosp, Dept Breast Oncol, Natori, Miyagi 9811293, Japan
[4] Tohoku Univ, Grad Sch Med, Dept Surg Oncol, Aoba Ku, Sendai, Miyagi 9808575, Japan
基金
日本学术振兴会;
关键词
Breast cancer; Survival; Body mass index; Hormone receptor; Menopausal status; YOUNG-WOMEN; GROWTH-FACTOR; ALL-CAUSE; OBESITY; MORTALITY; RISK; DISEASE; WEIGHT; HEIGHT; AGE;
D O I
10.1186/1471-2407-12-149
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Body mass index (BMI) may be an important factor affecting breast cancer outcome. Studies conducted mainly in Western countries have reported a relationship between higher BMI and a higher risk of all-cause death or breast cancer-specific death among women with breast cancer, but only a few studies have been reported in Japan so far. In the present prospective study, we investigated the associations between BMI and the risk of all-cause and breast cancer-specific death among breast cancer patients overall and by menopausal status and hormone receptor status. Methods: The study included 653 breast cancer patients admitted to a single hospital in Japan, between 1997 and 2005. BMI was assessed using a self-administered questionnaire. The patients were completely followed up until December, 2008. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated according to quartile points of BMI categories, respectively: <21.2, >= 21.2 to <23.3 (reference), >= 23.3 to <25.8 and >= 25.8 kg/m(2). Results: During the follow-up period, 136 all-cause and 108 breast cancer-specific deaths were observed. After adjustment for clinical and confounding factors, higher BMI was associated with an increased risk of all-cause death (HR = 2.61; 95% CI: 1.01-6.78 for BMI >= 25.8 vs. >= 21.2 to <23.3 kg/m(2)) among premenopausal patients. According to hormonal receptor status, BMI >= 25.8 kg/m(2) was associated with breast cancer-specific death (HR = 4.95; 95% CI: 1.05-23.35) and BMI <21.2 kg/m(2) was associated with all-cause (HR = 2.91; 95% CI: 1.09-7.77) and breast cancer-specific death (HR = 7.23; 95% CI: 1.57-33.34) among patients with ER + or PgR + tumors. Analysis by hormonal receptor status also showed a positive association between BMI and mortality risk among patients with ER + or PgR + tumors and with BMI >= 21.2 kg/m(2) (p for trend: 0.020 and 0.031 for all-cause and breast cancer-specific death, respectively). Conclusions: Our results suggest that both higher BMI and lower BMI are associated with an increased risk of mortality, especially among premenopausal patients or among patients with hormonal receptor positive tumors. Breast cancer patients should be informed of the potential importance of maintaining an appropriate body weight after they have been diagnosed.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Body mass index and survival after breast cancer diagnosis in Japanese women
    Masaaki Kawai
    Yuko Minami
    Yoshikazu Nishino
    Kayoko Fukamachi
    Noriaki Ohuchi
    Yoichiro Kakugawa
    BMC Cancer, 12
  • [2] Body mass index and survival after breast cancer diagnosis in Japanese women
    Kawai, M.
    Minami, Y.
    Nishino, Y.
    Ohuchi, N.
    Kakugawa, Y.
    CANCER RESEARCH, 2012, 72
  • [3] Body mass index and prognosis after breast cancer diagnosis in Japanese women
    Yamashita, Toshinari
    Aruga, Tomoyuki
    Miyamoto, Hiromi
    Horiguchi, Kazumi
    Honda, Yayoi
    Idera, Nami
    Goto, Risa
    Kuroi, Katsumasa
    CANCER RESEARCH, 2015, 75
  • [4] Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project
    Marilyn L. Kwan
    Wendy Y. Chen
    Candyce H. Kroenke
    Erin K. Weltzien
    Jeannette M. Beasley
    Sarah J. Nechuta
    Elizabeth M. Poole
    Wei Lu
    Michelle D. Holmes
    Charles P. Quesenberry
    John P. Pierce
    Xiao Ou Shu
    Bette J. Caan
    Breast Cancer Research and Treatment, 2012, 132 : 729 - 739
  • [5] Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project
    Kwan, Marilyn L.
    Chen, Wendy Y.
    Kroenke, Candyce H.
    Weltzien, Erin K.
    Beasley, Jeannette M.
    Nechuta, Sarah J.
    Poole, Elizabeth M.
    Lu, Wei
    Holmes, Michelle D.
    Quesenberry, Charles P., Jr.
    Pierce, John P.
    Shu, Xiao Ou
    Caan, Bette J.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (02) : 729 - 739
  • [6] Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry
    Kawai, Masaaki
    Tomotaki, Ai
    Miyata, Hiroaki
    Iwamoto, Takayuki
    Niikura, Naoki
    Anan, Keisei
    Hayashi, Naoki
    Aogi, Kenjiro
    Ishida, Takanori
    Masuoka, Hideji
    Iijima, Kotaro
    Masuda, Shinobu
    Tsugawa, Koichiro
    Kinoshita, Takayuki
    Nakamura, Seigo
    Tokuda, Yutaka
    CANCER MEDICINE, 2016, 5 (06): : 1328 - 1340
  • [7] The associations between body mass index and breast cancer intrinsic subtypes in Japanese women
    Kimura, K.
    Tanaka, S.
    Iwamoto, M.
    Uchiyama, K.
    CANCER RESEARCH, 2012, 72
  • [8] Association between body mass index and breast cancer intrinsic subtypes in Japanese women
    Kimura, Kosei
    Tanaka, Satoru
    Iwamoto, Mitsuhiko
    Fujioka, Hiroya
    Takahashi, Yuko
    Satou, Nayuko
    Uchiyama, Kazuhisa
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 4 (03) : 391 - 396
  • [9] Metastatic Breast Carcinoma in Women, Body Mass Index, and Survival
    Barron, Cynthia Reyes
    Planas-Silva, Maricarmen
    Hicks, David
    Turner, Bradley
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 242 - 244
  • [10] Metastatic Breast Carcinoma in Women, Body Mass Index, and Survival
    Barron, Cynthia Reyes
    Planas-Silva, Maricarmen
    Hicks, David
    Turner, Bradley
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 242 - 244